A recent collaboration between Belgian pharmaceutical group UCB and France-based Oncodesign aims at the development of innovative therapeutic treatments in neurodegenerative diseases. Within the framework of this collaboration, Oncodesign will apply its Nanocyclix technology* to identify next generation kinase inhibitors and UCB will provide its expertise in neurology. The collaboration will leverage the respective expertise of Oncodesign and UCB to bring innovative therapeutic solutions to patients suffering from neurodegenerative disorders. Oncodesign will apply its Nanocyclix technology on a kinase target selected by UCB with the aim of discovering potent and selective inhibitors that have the ability to cross the blood brain barrier. The agreement attributes UCB an exclusive licensing option of the program and, at the global level, the rights for commercialization and development.
“We are very excited to partner with UCB for the first time on this exclusive research collaboration and license option in the field of neurodegenerative disorders, an area with high unmet needs for a large patient population. This new collaboration demonstrates the growing interest that the pharmaceutical industry has in our Nanocyclix technology. This allows us to discover innovative inhibitors for kinases that are otherwise difficult to address,” said Jan Hoflack, Ph.D., chief scientific officer and head of Oncodesign’s discovery activities.
Congratulations to both UCB and Oncodesign for this exciting collaboration!
*Based on small molecule macrocyclisation, Nanocyclix technology is a proprietary medicinal chemistry platform that gives access to potent and highly selective kinase inhibitors with attractive physicochemical and ADME properties.
Laurent Schots, Media Relations, UCB
T +32.2.559.9264, email@example.com
France Nivelle, Global Communications, UCB
T +32 2 559 9178, firstname.lastname@example.org